Advertisement

  • News
  • Columns
  • Interviews
  • BW Communities
  • Events
  • BW TV
  • Subscribe to Print
  • Editorial Calendar 19-20

Latest Articles in glenmark

Glenmark Life Sciences Shares List With Over 4 % Gain

The stock listed at Rs 751.10, a gain of 4.31 per cent from the issue price on BSE. As trade progressed, it jumped 11.10 per cent to Rs 799.95.

Read More

Glenmark Life Sciences To Invest Rs 600 Cr To Double Capacity In Four Years

Glenmark Life Sciences is into select high value, non-commoditised APIs in chronic therapeutic areas like the cardiovascular, central nervous system, pain management and diabetes, apart from gastro-intestinal disorders, anti-infectives etc.

Read More

Glenmark Life Sciences IPO To Open On Jul 27; Price Band Set At Rs 695-720/Share

The public issue will have fresh issue of equity shares worth up to Rs 1,060 crore and sale of up to 63 lakh equity shares by Glenmark Pharma.

Read More

Glenmark Life Sciences IPO To Open Next Week

Glenmark Life Sciences had filed the red herring prospectus for the offer with the Registrar of Companies, Pune and it was taken on record by the ROC the next day, Glenmark Pharma said in a BSE filing.

Read More

Glenmark Pharma Launches COPD Treatment Inhaler In UK

Glenmark's subsidiary Glenmark Pharmaceuticals Europe Ltd had entered into a strategic and exclusive in-licensing arrangement for marketing generic Tiotropium Bromide DPI in Western Europe and the UK in August 2018.

Read More

Glenmark Says Interim Data From Study Supports Favipiravir's Safety, Effectiveness

Glenmark received restricted emergency use approval from India's drug regulator for FabiFlu for the treatment of mild to moderate COVID-19.

Read More

Glenmark Q4 Net Profit Up 6 % At Rs 233.87 Cr

The company's revenue from operations stood at Rs 10,943.9 crore for the fiscal ended March 2021. It was Rs 10,641 crore in 2019-20

Read More

Glenmark Pharma Gets USFDA Nod For Icatibant Injection

The drug firm said its current portfolio consists of 172 products authorised for distribution in the US marketplace and 44 abbreviated new drug applications are pending approval with the USFDA.

Read More

Glenmark Pharma To Launch Its Nasal Spray Ryaltris In EU

Ryaltris is indicated for symptomatic treatment of seasonal and perennial allergic rhinitis in adults and children over 12 years of age.

Read More

Glenmark receives one ANDA approval and two tentative ANDA approvals - Tadalafil Gabapentin Enacarbil and Apremilast

Glenmark receives one ANDA approval and two tentative ANDA approvals - Tadalafil Gabapentin Enacarbil and Apremilast

Read More

Glenmark becomes the first company to launch Remogliflozin + Vildagliptin fixed dose combination, at an affordable price for adults with Type 2 Diabetes in India

Glenmark becomes the first company to launch Remogliflozin + Vildagliptin fixed dose combination, at an affordable price for adults with Type 2 Diabetes in India

Read More

Glenmark Pharmaceuticals and Menarini enter into exclusive licensing agreement for commercializing Ryaltris™ nasal spray across numerous markets throughout Europe

Glenmark Pharmaceuticals and Menarini enter into exclusive licensing agreement for commercializing Ryaltris™ nasal spray across numerous markets throughout Europe

Read More

Glenmark Pharma Gets Tentative Nod From USFDA For Anticoagulant Drug

Quoting IQVIA sales data for the 12 month period ending August 2020, Glenmark said Pradaxa capsules, 75, 110 mg and 150 mg, market achieved annual sales of approximately USD 550.9 million.

Read More

Glenmark to divest select Anti-Allergy brands to Dr Reddy's in Russia, Ukraine, Kazakhstan and Uzbekistan in anticipation of its "Ryaltris" Launch

Glenmark to divest select Anti-Allergy brands to Dr Reddy's in Russia, Ukraine, Kazakhstan and Uzbekistan in anticipation of its "Ryaltris" Launch

Read More

Glenmark Pharma Gets USFDA Nod For Generic Drug

The company's US-based subsidiary has received final approval from the US Food and Drug Administration (USFDA) for the product which is a generic version of PF Prism CV's Rapamune tablets

Read More